End Of Medicare As We Know It: AMA

5 December 1994

Testifying before the Physician Payment Review Commission, James Todd, executive vice president of the American Medical Association, noted that whether Medicare changes are based on health reform or deficit reduction, the result would be the end of Medicare "as we and our patients know it."

He also noted that many doctors already lose money treating elderly patients, and the situation could worsen. According to the Commission's own figures, Medicare now pays doctors only 59 cents for services that private insurers pay $1. And a new round of cuts could bring that Medicare figure down to just 34% of private payments by 2004, said Dr Todd. Other doctors testifying complained that some managed care plans are refusing to deal with some doctors, or are dropping those that signed up when a company first entered the market.

The Commission advises Congress on physician pay.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight